BioPharmSignal logoBioPharmSignal

Biotech News

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

Charles River (CRL)Charles RiverFDA / regulatory

Charles River platform offers 40% reduction in cell bank production timeline, over the industry standard of 20 weeks WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 17, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly

Related news

CRLCharles River2026-06-18 12:00 EST

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

CRLCharles River2026-09-11 12:00 EST

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

View all latest news

Charles River

Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and...

Recent company news

CRLCharles River2026-09-24 12:00 EST

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day

CRLCharles River2026-09-17 12:00 EST

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

CRLCharles River2026-09-11 12:00 EST

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

CRLCharles River2026-09-08 12:00 EST

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

CRLCharles River2026-08-20 12:00 EST

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

Stock data

Close
290.19 USD
Market cap
8.42B USD
Exchange
NYSE
Sector
Biopharma
Location
United States